Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus INDOCIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus INDOCIN SR.
ALEVE vs INDOCIN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins, which mediate inflammation, pain, and fever. It also has a direct effect on renal blood flow and platelet aggregation.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
75 mg orally once daily, extended-release capsules.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Terminal half-life is 4.5 hours (range 2.6-11.2 hours) in young adults; prolonged in elderly (up to 16 hours) and in patients with renal or hepatic impairment.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Approximately 50% renal (as unchanged drug and metabolites, primarily glucuronide conjugates), 33% biliary/fecal. Indomethacin undergoes enterohepatic recirculation.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)